Education
About Us
Working with TipRanks
Follow Us
Amgen (AMGN)
NASDAQ:AMGN
AMGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$253.30 - $339.17
Previous CloseN/A
Volume614.18K
Average Volume (3M)2.08M
Market Cap
$150.84B
Enterprise Value$199.23B
Total Cash (Recent Filing)$8.03B
Total Debt (Recent Filing)$56.20B
Price to Earnings (P/E)22.9
Beta0.39
Next Earnings
Oct 29, 2025EPS Estimate
5.04Last Dividend Ex-Date
Aug 22, 2025Dividend Yield3.35%
Share Statistics
EPS (TTM)6.02
Shares Outstanding538,361,900
10 Day Avg. Volume1,997,853
30 Day Avg. Volume2,075,124
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue5.71
Enterprise Value/Gross Profit8.85
Enterprise Value/Ebitda12.53
Forecast
1Y Price Target
$323.47Price Target Upside15.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
Bulls Say, Bears Say
Bulls Say
EarningsAMGN reported earnings per share significantly above consensus expectations, leading to an increase in full-year 2025 earnings guidance.
Product PerformanceSeveral key products showed strong sales performance, exceeding consensus expectations and contributing to the revenue upside.
Revenue GuidanceThe company increased its full-year 2025 revenue guidance, indicating confidence in its future performance.
Bears Say
Market ChallengesBemarituzumab has a limited market opportunity and therefore is not a major value driver for Amgen.
Price ControlsLong-term Repatha risks remain, with anticipated Medicare Part D IRA price controls and potential biosimilar competition after loss of exclusivity.
Safety ConcernsKnown safety issues with ocular toxicity contribute to caution about bemarituzumab's opportunity following the FORTITUDE-101 announcement.
Amgen News
AMGN FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest stock price was $253.30 and its highest was $339.17 in the past 12 months.
What is Amgen’s market cap?
Amgen’s market cap is $150.84B.
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is Oct 29, 2025 which is in 48 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on Aug 05, 2025. The company reported $6.02 earnings per share for the quarter, beating the consensus estimate of $5.281 by $0.739.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen pays a Quarterly dividend of $2.38 which represents an annual dividend yield of 3.35%. See more information on Amgen dividends here
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is 5.04.
How many shares outstanding does Amgen have?
Amgen has 538,361,900 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of $6.02 in its last earnings report, beating expectations of $5.281. Following the earnings report the stock price went down -5.133%.
Which hedge fund is a major shareholder of Amgen?
Currently, no hedge funds are holding shares in AMGN
Amgen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$323.47 (15.54% Upside)
$323.47 (15.54% Upside)
Blogger Sentiment
Bullish
AMGN Sentiment 81%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.22%
12-Months-Change
Fundamentals
Return on Equity
99.14%
Trailing 12-Months
Asset Growth
-3.31%
Trailing 12-Months
Company Description
Amgen
Amgen Inc. is a leading biotechnology company based in the United States, focused on discovering, developing, manufacturing, and delivering innovative human therapeutics. Established in 1980, Amgen operates primarily in the biopharmaceutical sector, specializing in the areas of oncology, nephrology, rheumatology, and other serious diseases. The company is known for its core products including Enbrel, Neulasta, and Prolia, which are designed to treat a variety of medical conditions through advanced biotechnology techniques.
AMGN Company Deck
AMGN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Amgen's Q2 2025 earnings call highlighted strong revenue and volume growth, driven by significant increases in sales of key products and a robust rare disease portfolio. The company also demonstrated progress in its R&D pipeline. However, challenges remain with pricing pressures and regulatory changes. Despite these challenges, the positive aspects of the call outweigh the negatives.View all AMGN earnings summariesAMGN Revenue Breakdown
13.09% Prolia
9.92% Enbrel
6.66% XGEVA
6.65% Repatha
63.69% Other
AMGN Stock 12 Month Forecast
Average Price Target
$323.47
▲(15.54% Upside)
Technical Analysis
Ownership Overview
0.19% Insiders
24.39% Mutual Funds
22.22% Other Institutional Investors
24.47% Public Companies and Individual Investors